AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03520790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.
Study NCT00000259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3 % Sevoflurane
Study NCT00000259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% Nitrous oxide
Study NCT00000259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.6% Sevoflurane
Study NCT00000259 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01264536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactoferrin
Description: Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
Study NCT01264536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
Study NCT02498106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orthica Soft Multi Mini and Orthica Fish EPA Mini
Description: daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins \[B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene\] and minerals \[Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese\]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid \[EPA\] and docosahexaenic acid \[DHA\])
Study NCT02498106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orthica Soft Multi Mini and Orthica Fish EPA Mini
Description: daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins \[B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene\] and minerals \[Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese\]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid \[EPA\] and docosahexaenic acid \[DHA\])
Study NCT02003521 — intervention group
Intervention type: DEVICE
Intervention: Lung Flute
Description: A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
Study NCT02565173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 4.5% BID
Description: Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
Study NCT02565173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 6.0% QD
Description: Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
Study NCT02565173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 3.0% QD
Description: Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
Study NCT02565173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol 0.5% BID
Description: Timolol 0.5% administered twice per day in both eyes for 12 weeks.
Study NCT02565173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo BID
Description: Placebo administered twice per day in both eyes for 12 weeks.
Study NCT01635218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment
Description: A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
Study NCT01635218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
Study NCT01635218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
Study NCT01455311 — intervention group
Intervention type: PROCEDURE
Intervention: EUS Guided Fine Needle Aspiration
Description: EUS-guided fine needle aspiration of the cyst fluid
Study NCT01455311 — intervention group
Intervention type: PROCEDURE
Intervention: EUS Guided EchoBrush Sampling
Description: EUS-guided brushing of the cyst wall
Study NCT01470495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RFA + Sorafenib
Description: combined RFA and Sorafenib to treat recurrent HCC
Study NCT03520790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00741104 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: Treatment of RA with Infliximab according to and under normal routine clinical practice.
Study NCT03556982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-123 cells
Description: CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
Study NCT03185923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM plus conventional drug
Description: All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical \& Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days.
Study NCT02246621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02246621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally
Study NCT02246621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole
Description: Administered orally
Study NCT02246621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered orally
Study NCT02246621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Administered orally
Study NCT02246621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03185923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM placebo plus conventional drug
Description: All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days.
Study NCT02481791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil and/or propofol
Description: Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
Study NCT04689204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTA30X
Description: CTA30X cell injection by intravenous infusion
Study NCT04350138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B Vaccine
Description: A combination vaccine consisting of rMenB and OMV NZ.
Study NCT02481791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil and/or propofol
Description: Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
Study NCT04350138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mM sodium chloride (0.9% saline solution).
Study NCT02998528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT02481791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
Study NCT00831857 — intervention group
Intervention type: OTHER
Intervention: 89Zr-Bevacizumab PET-scan
Description: At baseline, after two weeks of treatment and after 6 weeks of treatment.
Study NCT02443051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Computer delivered modification in 80% of trials
Study NCT02443051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification
Description: Computer delivered modification in 80% of trials
Study NCT02774291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT02774291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes
Description: Given IV
Study NCT02774291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02774291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT02774291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IVPB
Study NCT02774291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02187224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Study NCT02187224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Progesterone)
Study NCT04134377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Food Snack
Description: The intervention is 6-months using a food snack with control being three months prior to and three months after-study invention whereby serum albumin levels will be collected monthly. If patients are participating in a supplement program, they will be maintained throughout all ten months of the study so long as the criteria for the supplement program (enrollment and discontinuation) is still being met.
Study NCT00644241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell harvest
Description: stem cells will be harvested from the iliac crest of the patients
Study NCT00644241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angiographic transplantation of stem cells
Description: autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
Study NCT02325804 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
Study NCT03726541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: Physiotherapy program includes breathing exercises, incisive spirometer study, grade ambulation. Oxygen saturation, heart rate and blood pressure values will be recorded before and after the session. Changes in the follow-up parameters will be discussed.
Study NCT01193049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period
Study NCT01193049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets as a single oral dose on Day 1 of each study period
Study NCT03535090 — intervention group
Intervention type: DRUG
Intervention: Methylprednisolone
Study NCT02126527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: auranofin
Description: Given PO
Study NCT02126527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Specified dose on specified days
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Specified dose on specified days
Study NCT02126527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02126527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00910936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks endurance training, 3 times weekly for 35 minutes
Study NCT04146402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10A+chemo
Description: SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
Study NCT04146402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos+chemo
Description: Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Specified dose on specified days
Study NCT02829606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: small scotoma using Head Mounted Display No re-mapping
Description: re-mapping software turned off
Study NCT02829606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large scotoma using Head Mounted Display PLUS re-mapping
Description: re-mapping software turned on
Study NCT01779895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei probiotic strain
Study NCT01779895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltodextrin
Study NCT04483752 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CHEST CT SCAN
Description: Chest CTscan at 3 and 12 months
Study NCT00887068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 32 mg/m\^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT02092324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02092324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02092324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02092324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT02977533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402668
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02977533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02977533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02977533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyclovir
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02933372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
Study NCT02221960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6383
Description: Subjects will receive MEDI6383 until disease progression or adverse event.
Study NCT02221960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6383 and MEDI4736
Description: Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
Study NCT01945788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide (rDNA origin)
Study NCT01945788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide (rDNA origin)
Study NCT01063946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombrabulin (AVE8062)
Description: Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion
Study NCT02863861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine
Study NCT02863861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol-ketamine
Study NCT01372813 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vandetanib
Description: Daily dose 300mg/day by mouth, 28 day cycle
Study NCT01406158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate Formulation A
Description: oral suspension
Study NCT01406158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate Formulation B
Description: oral suspension
Study NCT01406158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: oral tablet
Study NCT02451254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: circumferential ablation
Description: circumferential ablation of the pulmonary veins
Study NCT02451254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SVT ablation
Description: SVT ablation
Study NCT00910013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.5% intra-articular ropivacaïne (20cc)
Study NCT03696004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC-100
Description: Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days